IMAC Holdings, Inc. (BACK)
OTCMKTS · Delayed Price · Currency is USD
0.0600
0.00 (0.00%)
Jul 25, 2025, 9:41 AM EDT
IMAC Holdings Revenue
IMAC Holdings had revenue of $1.50K in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $73.55K. In the year 2024, IMAC Holdings had annual revenue of $72.05K.
Revenue (ttm)
73.55K
Revenue Growth
n/a
P/S Ratio
3.09
Revenue / Employee
4.90K
Employees
15
Market Cap
227.10K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 72.05K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 14.39M | 1.55M | 12.08% |
| Dec 31, 2020 | 12.84M | -2.29M | -15.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| American Oncology Network | 1.76B |
| Silence Therapeutics | 27.70M |
IMAC Holdings News
- 5 months ago - Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference - GlobeNewsWire
- 5 months ago - Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay - GlobeNewsWire
- 5 months ago - Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response - GlobeNewsWire
- 6 months ago - IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies - GlobeNewsWire
- 8 months ago - IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q - GlobeNewsWire
- 9 months ago - IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1) - GlobeNewsWire
- 11 months ago - IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology - GlobeNewsWire
- 1 year ago - IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors - GlobeNewsWire